Overview
Procainamide is a class IA antiarrhythmic drug used in the treatment of both ventricular and supraventricular arrhythmias. It works by blocking fast sodium channels, which slows myocardial conduction velocity, and by blocking potassium channels, which prolongs repolarization and increases action potential duration. It also reduces pacemaker cell automaticity and suppresses re-entry mechanisms responsible for arrhythmias.
It is particularly useful in managing arrhythmias associated with Wolff–Parkinson–White syndrome. It is metabolized in the liver to an active metabolite, N-acetylprocainamide, which also possesses antiarrhythmic properties and contributes to the overall therapeutic effect.
Symptoms
Symptoms related to procainamide are usually due to adverse effects or toxic levels rather than the drug’s intended action. Common symptoms include dizziness, nausea, vomiting, hypotension, bradycardia, and fatigue. Cardiac-related symptoms such as palpitations or worsening arrhythmias may occur due to QT prolongation and proarrhythmic effects, including torsades de pointes.
Neurological symptoms such as confusion and lightheadedness can be seen. Long-term therapy may lead to drug-induced lupus erythematosus, presenting with joint pain, fever, rash, and malaise.
Causes
Adverse effects and toxicity of procainamide are caused by excessive sodium and potassium channel blockade and accumulation of the drug or its metabolite. Reduced renal clearance leads to accumulation of procainamide and N-acetylprocainamide, increasing the risk of arrhythmias and hypotension.
Hepatic impairment reduces acetylation, resulting in higher procainamide levels. Rapid intravenous administration can cause severe hypotension. Chronic exposure is associated with autoimmune reactions leading to lupus-like syndrome.
Risk Factors
Risk factors for toxicity include renal impairment, hepatic dysfunction, advanced age, and prolonged therapy.
Patients with pre-existing conduction abnormalities, prolonged QT interval, or heart failure are at increased risk of proarrhythmia. Slow acetylators accumulate higher levels of these and are more prone to adverse effects. Concomitant use of other QT-prolonging drugs further increases the risk of torsades de pointes.
Prevention
Prevention focuses on careful dosing, therapeutic drug monitoring, and regular clinical assessment. Monitoring procainamide and N-acetylprocainamide levels helps maintain concentrations within the therapeutic range and prevents toxicity. Dose adjustment is essential in renal and hepatic impairment.
Slow intravenous administration reduces the risk of hypotension. Regular ECG monitoring helps detect QT prolongation and arrhythmias early. Early recognition of lupus-like symptoms and prompt discontinuation of the drug help prevent long-term complications and improve patient safety.
